News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
680,987 Results
Type
Article (38928)
Company Profile (265)
Press Release (641794)
Section
Business (203844)
Career Advice (1983)
Deals (35376)
Drug Delivery (80)
Drug Development (80796)
Employer Resources (167)
FDA (16052)
Job Trends (14802)
News (344316)
Policy (32441)
Tag
Academia (2530)
Africa (712)
Alliances (49076)
Alzheimer's disease (1160)
Approvals (15981)
Arizona (178)
Artificial intelligence (86)
Asia (36947)
Australia (6026)
Bankruptcy (351)
Best Places to Work (11357)
Biosimilars (65)
Biotechnology (191)
Breast cancer (74)
C2C Services and Suppliers (78802)
California (2130)
Canada (1014)
Cancer (622)
Career advice (1651)
Cell therapy (150)
China (166)
Clinical research (63529)
Collaboration (195)
Colorado (88)
Compensation (112)
Connecticut (89)
COVID-19 (2506)
Cystic fibrosis (78)
Data (473)
Diabetes (98)
Diagnostics (6011)
Drug pricing (72)
Earnings (83726)
Employer resources (142)
Europe (78978)
Events (108237)
Executive appointments (184)
FDA (16357)
Florida (309)
Funding (187)
Gene therapy (106)
Georgia (68)
GLP-1 (526)
Government (4306)
Healthcare (18634)
Hotbed/Location (481279)
Illinois (274)
Indiana (155)
Infectious disease (2547)
Inflammatory bowel disease (94)
Interviews (307)
IPO (16229)
Job creations (3629)
Job search strategy (1415)
Kansas (94)
Layoffs (400)
Legal (7838)
Lung cancer (122)
Manufacturing (112)
Maryland (442)
Massachusetts (1738)
Medical device (13075)
Medtech (13080)
Mergers & acquisitions (19066)
Metabolic disorders (286)
Michigan (132)
Minnesota (228)
Neuroscience (1341)
New Jersey (652)
New York (666)
NextGen Class of 2024 (6493)
Non-profit (4458)
North Carolina (614)
Northern California (926)
Obesity (173)
Ohio (115)
Opinion (172)
Patents (80)
Pennsylvania (633)
People (56015)
Phase I (19692)
Phase II (27973)
Phase III (20901)
Pipeline (140)
Postmarket research (2551)
Preclinical (8353)
Radiopharmaceuticals (230)
Rare diseases (151)
Real estate (5897)
Regulatory (21314)
Research institute (2307)
Resumes & cover letters (348)
South America (1090)
Southern California (860)
Startups (3567)
Texas (277)
United States (9503)
Vaccines (493)
Washington State (267)
Weight loss (139)
Date
Last 7 days (652)
Last 30 days (2526)
Last 365 days (36582)
2024 (27515)
2023 (40102)
2022 (51230)
2021 (55764)
2020 (54127)
2019 (46568)
2018 (35042)
2017 (32146)
2016 (31522)
2015 (37590)
2014 (31361)
2013 (26383)
2012 (28585)
2011 (29284)
2010 (27353)
680,987 Results for "sillajen biotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC
SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
March 27, 2024
·
5 min read
Business
Mid-Atlantic BioTherapeutics, Inc. and SMITM Capital Markets Ltd enter into a significant financing agreement
SMITM CAPITAL MARKETS LTD, has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT), a clinical-stage ready US biopharmaceutical company.
June 19, 2024
·
4 min read
Biotech Beach
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 07, 2024
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 9,700 restricted stock units of Atara’s common stock to one newly hired employee.
June 7, 2024
·
2 min read
Deals
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
Calidi Biotherapeutics, Inc. today announced the pricing of its “reasonable best efforts” public offering of 15,197,500 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A Common Warrants.
April 16, 2024
·
5 min read
Biotech Beach
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
Calidi Biotherapeutics, Inc. announced the closing of its previously announced public offering of 15,197,500 shares of common stock and accompanying Series A Common Warrants, Series B Unit Warrants, with each unit consisting of one share of common stock and a Series B-1 Common Warrant and Series C Unit Warrants.
April 19, 2024
·
4 min read
Biotech Beach
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 05, 2024
Atara Biotherapeutics, Inc. reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee.
April 5, 2024
·
2 min read
Biotech Beach
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2024
Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of 4,150 restricted stock units of Atara’s common stock to one newly hired employee.
May 3, 2024
·
2 min read
Deals
Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split
Atara Biotherapeutics, Inc. today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 (the “Reverse Stock Split”).
June 17, 2024
·
5 min read
Business
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
Calidi Biotherapeutics, Inc. today announced the appointment of Dr. George E. Peoples, MD, FACS, to the company’s Board of Directors, effective July 1, 2024.
June 27, 2024
·
4 min read
Protalix BioTherapeutics to Present at the 2024 BIO International Convention
Protalix BioTherapeutics, Inc. announced that Dror Bashan, its President and Chief Executive Officer, will present at the upcoming 2024 BIO International Convention June 3 - 6, 2024, in San Diego, California.
May 29, 2024
·
3 min read
1 of 68,099
Next
